GK530G

DRUG2 trials

Sponsors

Galderma R&D

Conditions

Acne Vulgaris

Phase 3

A Long Term Study of GK530G in Subjects With Acne Vulgaris

CompletedNCT01910064

Galderma R&DAcne Vulgaris

Start: 2013-05-31End: 2014-08-31Updated: 2017-03-28

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

CompletedNCT02073448

Galderma R&DAcne Vulgaris

Start: 2014-03-31End: 2014-10-31Updated: 2017-03-28